Inspira Technologies has announced the development of a new disposable kit featuring a built-in performance monitoring mechanism, designed for the perfusion market.

This product aligns with the company's strategy to generate recurring revenue and is expected to be compatible with various life-support machines, potentially addressing the $1bn perfusion systems market.

The disposable kit is a single-use product that alerts medical teams to any changes in performance during operation and treatment.

Its unique design is intended to offer a smart, adaptable experience for users.

Inspira Technologies co-founder and CEO Dagi Ben-Noon said: “This new innovation and capability, being integrated into our disposable kit, is expected to be an additional step by Inspira to provide new technologies and user experiences for the purpose of supporting improved safety and patient care.”

Inspira is preparing to submit an application for US FDA clearance to market the disposable kit.

Upon approval, the kit will be available for hospitals using the INSPIRA ART100 system.

The ART100 system received FDA 510(k) clearance for cardiopulmonary bypass procedures in May this year.

The company expects the first devices to be deployed in the US by the end of 2024.

Inspira received approval from the Israeli Ministry of Health for its INSPIRA ART100 system in July this year.

The company has developed INSPIRA ART with the aim of transforming the $19bn mechanical ventilation market.

INSPIRA ART features the clip-on HYLA blood sensor, a real-time continuous monitoring technology that alerts physicians to patient condition changes without needing blood samples, helping them make informed decisions.